Trials / Completed
CompletedNCT01854567
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
A 1-Year, Multicenter, Randomized, Open-Label Controlled Study to Evaluate the Efficacy and Safety of Cord Blood Cells Expanded With MPCs for Hematopoetic Recovery in Patients With Hematologic Malignancies After Myeloablative Treatment
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Mesoblast, Ltd. · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
The study investigates the time to engraftment of a mesenchymal expanded cord blood unit in patients with hematologic malignancies undergoing transplantation with myeloablative conditioning.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Infusion of one MPC expanded cord unit and one unexpanded cord unit | Infusion of one MPC expanded cord unit and one unexpanded cord unit. |
| BIOLOGICAL | Infusion of two unexpanded cord blood units. | Umbilical Cord Blood. |
Timeline
- Start date
- 2013-08-01
- Primary completion
- 2016-09-23
- Completion
- 2017-05-05
- First posted
- 2013-05-15
- Last updated
- 2020-06-26
Locations
9 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT01854567. Inclusion in this directory is not an endorsement.